- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04491136
Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM) (RHYTHM)
A Multicenter, Interventional, Open-label and Single-arm Study to Investigate the Effect of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D
Study Overview
Detailed Description
The rationale of this study is to compare the effect of ACEI/ARB with the effect of ARNI on VA events for HFrEF patients with ICD or CRT-D, thus a multicenter, interventional, open-label, and prospective single-arm study was considered.
Study design:This will be a multicenter, interventional, open-label, and prospective single-arm study to evaluate the effect of ARNI on VAs in approximately 219 HFrEF patients receiving ICD or CRT-D in China.
After the patient is informed and asked to sign an informed consent form, baseline data will be collected. Device data of patients will be collected for 12 months. ACEI/ARB will be given to the patient for 6 months. Dosage of ACEI/ARB will be based on investigator's discretion and up titrated after 2-4 weeks to the maximum dosage the patients can tolerate and according to product label.After 6 months, patients using ACEI need to undergo a 36-hr washout period (36-hr washout period is not needed for patients using ARB at month 6). Patients will then receive ARNI (sponsored by Novartis only for this study) while the dosage of ARNI will be according to investigator's discretion and up titrated to the maximum dosage the patient can tolerate or 200 mg bid as per guideline.All patients will be followed up for 6 months for each treatment. After patients finalize the trial, the investigator will evaluate all patients and produce a report.
Primary objective of this study is to assess the proportion of patients with VA events over 6 months of ACEI/ARB and 6 months of ARNI treatment.
Secondary Objectives include:To assess numbers of occurrences of VA events and ICD or CRT-D shocks over 6 months of ACEI/ARB and 6 months of ARNI treatment; To compare the changes in LVEF and NYHA level between ACEI/ARB and ARNI treatment; To compare the changes in the NT-proBNP level between ACEI/ARB and ARNI treatments; To compare the healthcare resource utilization of HF patients during ACEI/ARB and ARNI treatments;
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Guangzhou, China, 510000
- Novartis Investigative Site
-
Tianjin, China, 300000
- Novartis Investigative Site
-
-
An Hui
-
Hefei, An Hui, China, 230001
- Novartis Investigative Site
-
-
Bei Jing
-
Bei Jing, Bei Jing, China, 100034
- Novartis Investigative Site
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Novartis Investigative Site
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Novartis Investigative Site
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518057
- Novartis Investigative Site
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Novartis Investigative Site
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Novartis Investigative Site
-
Nantong, Jiangsu, China, 226000
- Novartis Investigative Site
-
Wu XI, Jiangsu, China, 214023
- Novartis Investigative Site
-
Xuzhou, Jiangsu, China, 221000
- Novartis Investigative Site
-
-
Liaoning
-
Dalian, Liaoning, China, 116011
- Novartis Investigative Site
-
Shenyang, Liaoning, China, 110011
- Novartis Investigative Site
-
-
Shandong
-
Qingdao, Shandong, China, 266003
- Novartis Investigative Site
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Novartis Investigative Site
-
Shanghai, Shanghai, China, 200433
- Novartis Investigative Site
-
-
Shanxi
-
Xian, Shanxi, China, 710061
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Novartis Investigative Site
-
Chengdu, Sichuan, China, 610031
- Novartis Investigative Site
-
-
Xinjiang
-
Wulumuqi, Xinjiang, China, 830054
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310014
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion criteria:
- Male or female patients ≥18 and ≤80 years of age
- Implanted with an ICD or CRT-D within 2 weeks
- NYHA functional class II - IV
- LVEF ≤40% (measured by echocardiography)
- Signed informed consent must be obtained prior to participation in the study.
Key Exclusion criteria
- History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes.
- Patient received target dose (≥200 mg/d) of ARNI for 2 weeks continuously within the 6-week period prior to study enrollment.
- Participation in other clinical studies 3 months prior to participating study.
- Advanced cancer or other significant comorbidities with life expectancy of <1 year.
- Previous history of angioedema associated with ACEI/ARB treatment, hereditary or idiopathic angioedema.
- Patients with renal artery stenosis history.
- Current stage D HF patients requiring vasoactive drugs.
- Symptomatic hypotension < 100/60 mmHg at visit 1 (screening) or Symptomatic hypotension < 90/60 mmHg in anti-hypertension drug treatment at visit 1 (screening).
- Serum potassium >5.4 mmol/L at visit 1 (screening).
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 as measured at visit 1 (screening).
- Pregnant or nursing (lactating) women.
- Other exclusion depend on investigator's discretion.
Other protocol- defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACEI/ARB treatment in 6 months/ARNI treatment in next 6 months
Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers treatment in the first 6 months Angiotensin receptor neprilysin inhibitor treatment in next 6 months |
initative ACE/ARB drug for 6 months in this study
initative ARNI drug for next 6 months in this study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with VA, ICD and ATP events over 6 months of ACEI/ARB and 6 months of ARNI treatment
Time Frame: Up to 12 months
|
Paired proportion of patients by occurrence of at least one Ventricular arrhythmia (VA), Implantable cardioverter defibrillator (ICD ) & Antitachycardia pacing (ATP) event over 6 months of Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers(ACEI/ARB) & Angiotensin receptor neprilysin inhibitor (ARNI) treatment respectively. VA events defined as: NSVT(Non-sustained ventricular tachycardia), SVT(Sustained ventricular tachycardia),PVC(Premature ventricular contraction), SVT is defined as: tachycardia with haemodynamic disorder or lasting for ≥30 seconds. NSVT is defined as: different ICD devices. PVC is defined as: early ventricular depolarization as determined by device. ICD events: Ventricular tachycardia occurrence in implantable cardioverter defibrillator (ICD) patients may result in shock delivery & is associated with increased morbidity & mortality. ATP events: Anti-tachycardia pacing is defined as a low-energy alternative to high-energy biphasic shocks. |
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numbers of NSVT, SVT, PVC, ICD shock and ATP experienced by patients
Time Frame: baseline, 6 month, 12 month
|
To assess the number of occurrences of Ventricular arrhythmia (VA) events and Implantable cardioverter defibrillator (ICD) or Cardiac resynchronization therapy-defibrillator (CRT-D) shocks over 6 months of ACEI/ARB and 6 months of ARNI treatment
|
baseline, 6 month, 12 month
|
LVEF (%)
Time Frame: baseline, 6 month, 12 month
|
To compare the changes in Left Ventricular Ejection Fraction (LVEF) between ACEI/ARB and ARNI treatments
|
baseline, 6 month, 12 month
|
NYHA level
Time Frame: baseline, 6 month, 12 month
|
To compare the changes in New York Heart Association (NYHA) level between ACEI/ARB and ARNI treatments
|
baseline, 6 month, 12 month
|
NT-proBNP (pg/mL) level
Time Frame: baseline, 6 month, 12 month
|
To compare the changes in the N-Terminal prohormone of Brain Natriuretic Peptide(NT-proBNP) level between ACEI/ARB and ARNI treatments
|
baseline, 6 month, 12 month
|
Number of hospitalizations for arrhythmia or HF related hospitalizations
Time Frame: baseline, 6 month, 12 month
|
To compare the healthcare resource utilization of Heart Failure (HF) patients during ACEI/ARB and ARNI treatments
|
baseline, 6 month, 12 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLCZ696BCN04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
Clinical Trials on ACEI/ARB
-
University Hospital, Basel, SwitzerlandCompletedRAS Peptide Profile in Healthy VolunteersSwitzerland
-
Chinese University of Hong KongTerminatedHypertension | Non-DippingHong Kong
-
Lawson Health Research InstituteCompleted
-
State University of New York - Downstate Medical...TerminatedHypertension | HypotensionUnited States
-
University of PennsylvaniaUniversity of Arizona; Jordana B. Cohen, MD, MSCE; Thomas C. Hanff, MD, MPH; Department... and other collaboratorsCompleted
-
Ain Shams UniversityNot yet recruitingNephrotic Syndrome
-
University Hospital, Gentofte, CopenhagenCompleted
-
Children's Hospital of Fudan UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Shandong Provincial Hospital and other collaboratorsRecruitingKidney Diseases | Proteinuria | Hereditary NephropathyChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityBaoji Central Hospital; First Affiliated Hospital Xi'an Medical UniversityUnknownChronic Heart FailureChina
-
Consorci Sanitari de TerrassaInstitut Català de la Salut; Fundacio d'Investigacio en Atencio Primaria Jordi...RecruitingCOVID19 | ACE Inhibitors | ARB | Influenza Vaccination | Amantadine | Antihistamine AllergySpain